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Background. Metabolomics is a relatively new diagnostic tool that allows a deep insight into the body 
metabolism at a cellular level. 
Objective. This paper provides a comprehensive view into the metabolomics methodology and shows 
usefulness of this approach in diagnosing and stratifying lung and breast cancers. 
Methods. literature review of metabolomics studies and its clinical application in the diagnosis of cancer-
selected studies.
Results. in general, the metabolomic approach comprises three steps: 1) sampling and preparing biofluids 
or tissue homogenates, 2) identification of low-molecular weight compounds up to 1.0 kDa using nuclear magnetic 
resonance, mostly 1h-nMr and/or mass spectrometry, and finally 3) data processing and analysing. it is possible 
to identify a set of metabolites, which is specific for a certain metabolic status (the metabolic fingerprint). 
Furthermore, this set of metabolites provides information of possible pathomechanisms involved in the disease 
process i.e. information about the disease etiology. it has been proven that the change in metabolome precedes; 
not only clinical symptoms but other laboratory findings as well. Consequently, this approach, if sufficiently 
validated, seems to be very promising especially in screening and early diagnosing. 
Conclusions. it was demonstrated that metabolomic approach allows to discriminate patients with cancer 
from healthy persons, as well as to differentiate between clinical stages of the cancer. 
Key woRdS: metabolomics; metabolome; breast cancer; lung cancer.
Introduction
To understand the complex processes 
occurring in the living systems the holistic 
approach should be used within employing all 
established multilevel approaches, currently is 
called ‘omics science’. In general, there are 
more than 100 types of omics subjects, 
including sciences such as: genomics, 
transcriptomic, proteomics, and metabolomics. 
This approach includes all-important live 
processes from information storage trans crip-
tion processes, protein production, up to 
enzymes actions transforming certain 
substrates to products maintaining the cell 
l iving processes. while genomics and 
proteomics have been successfully introduced 
to routine diagnostics, metabolomics is still on 
the runway despite its assessed potential [1]. 
Metabolomics refers to the analysis and 
interpretation of ongoing processes in living 
organisms at the end of life chain consisting of 
genomics-transcriptomics-proteomics-meta-
bolo mics science. Metabolomics might be 
strongly influenced by external factors such as 
environment, life style, diet, medications, as well 
as by additional metabolite input from the body’s 
microbiomes. Metabolites are delineated as low-
molecular weight compounds (LMwC) up to 
1.0 kda. Those compounds are carbohydrates, 
fatty acids, lipids, amino acids, nucleosides, or 
other organic molecules which are involved in 
biochemical reactions as substrates, inter-
mediates, and/or final products. The set of body’s 
metabolites ultimately form its characteristic 
metabolome. Metabolome is a dynamic system, 
which is largely dependent on internal bio-
chemical reaction and external factors mentioned 
above [1, 2]. Metabolomics is a comparative 
science, e.g. the obtained information should be 
compared to the referenced one or vice versa. 
with this approach metabolomics can be 
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regarded as a diagnostic tool, which in principle 
enables to describe current metabolic status of 
cells, tissues, and organs. Simply put, it can define 
the general health of a living organism. This is 
done by analysing body fluids, either secreted 
like urine, saliva, mother milk, stool, or obtained 
during standard medical sampling procedures 
such as serum, plasma, cereb rospinal fluid, tissue 
samples etc.. The samples collection for meta-
bolomics studies is relatively simple, however 
certain procedures must be followed [3]. The 
patients must follow standard requirements: 
they should be fasting and reports all designated 
therapy, addictions, and medical history. The 
samples taken should be stored at -80 °C or 
preserved in liquid nitrogen [2, 4]. This low 
storage temperature ensures the maintaining of 
metabolic composition, i.e. minimalizing possible 
changes in the metabolic profile after sampling, 
and protects against potential influence of the 
donor’s microbiome [5, 6]. 
Comprehensive or even partial deter-
mination of the metabolome is not possible 
with a single analytical method due to different 
levels of detection limits and different group 
determination. There are many analytical 
methods employed for metabolomics, each of 
them having both advantages and dis ad van-
tages. However, there are two main methods, 
which are routinely used in metabolomics 
studies: NMR (Nuclear Magnetic Resonance, 
mostly 1H-NMR) and MS (Mass Spectrometry) 
hyphenated with separations techniques [2]. 
Studies based on both NMR and MS have a 
common pathway:
Raw sample preparation 
and/or extraction of 
metabolites
data collection
NMR/GC or LC-MS
data processing 
and data analysis
one of the most important advantages of 
the MS method is the sensitivity to femtomole 
concentration, which allows analysing up to 
several thousand molecules in a certain sample, 
resulting in precise molecular description in the 
tested specimen. on the other hand, repro-
ducibility with MS is usually worse as compared 
to NMR spectroscopy. Unlike the MS, the NMR 
method provides high reproducibility with the 
ability to combine structure analysis and 
detection of the range of 30-90 molecules 
without sample destruction (biofluids). 
However, the detection limit of individual 
compounds is shifted several rows and strongly 
depend on the time of measurements 
(acquisition). The advantage of this method is 
the ability to measure different compounds 
such as amino acids, nucleosides, amines, acids, 
etc. all at the same time. The data obtained with 
both methods are both quantitative and 
qualitative among the set of detected meta-
bolites [7]. 
The results obtained are further elaborated 
using chemometric multidimensional discri-
minatory methods. For this type of studies, the 
methods most commonly used are: unsu per-
vised PCA, supervised PLS (Partial Least Squares 
Fig. 1. Typical workflow for metabolomics studies [2].  
discriminant Analysis), and oPLS-dA (ortho-
gonal version of PLS-dA). These approaches 
allow describing each subject not with 2 or 3 
variables (chemical compounds or characteristic 
parameters) as in routine statistical analysis, 
but even hundreds of variables (chemical 
compounds - metabolites) can be analysed with 
selection of the most specific ones. Those 
compounds or more often sets of compounds 
can be employed as biomarkers for discri-
minating patients from healthy individuals or 
for staging of the disease [8]. 
application of metabolomics in the diagnosis 
of cancer – selected studies 
lung cancer 
In europe, lung cancer accounts for 
approximately 20 % of all cancer deaths, with 
376 000 deaths in 2008. Unfortunately, the early 
stages of this cancer are usually low-
symptomatic and final diagnosis is made late 
in the natural history of the disease. Conse-
quently, effective treatment is not possible up 
to 90 % of cases, and the overall 5-year survival 
rate is 11.2 % for men and 13.9 % for women 
[9]. The metabolomic studies of lung cancer are 
based on various body fluids, predominantly 
blood serum, urine, and saliva. The most 
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common type of lung cancer is non-small cell 
lung cancer (NSCLC). The main recognized risk 
factor for NSCLC is cigarette smoking. 
Additionally, CoPd is considered an independent 
risk factor of lung cancer [10]. our team has 
demonstrated a possibility to differentiate 
between patients with CoPd and with two 
stages of NSCLC: an early NSCLC (e-NSCLC) and 
an advanced NSCLC (A-NSCLC). Using 1H NMR 
method we were able to identify 45 metabolites 
in patients’ serum. Con centrations of acetate, 
citrate, and methanol were significantly 
reduced in lung cancer subjects. In contrast, 
concentrations of N-acetylated glycoproteins, 
leucine, lysine, mannose, choline, lipids (L3 + 
L4), and two other unknown compounds were 
increased in for patients suffering cancer in all 
three performed comparisons: NSCLC vs. 
CoPd, e NSCLC vs. CoPd and ANSCLC vs. CoPd 
[10]. Similar results were obtained by Musharraf 
et al [11]. Using GC-MS method for tracing 
metabolites in plasma, they were able to 
discriminate lung cancer patients from CoPd 
patients, as well as healthy non-smokers and 
healthy smokers with high sensitivity (96.2 %) 
and specificity (92.05 %).
Another research group focused on 
differentiating early lung cancer patients from 
healthy controls. They used 1HMR and rapid 
resolution liquid chromatography (RRLC) 
methods to investigate metabolites in serum 
and identified 25 metabolites, which were up 
or down regulated. Those findings proved 
disorders in glycolysis, lipid metabolism, 
choline phospholipid metabolism, one-carbon 
metabolism, and amino acid metabolism. The 
use of both methods enabled diagnosing early 
stage of lung cancer with a very high accuracy 
[12]. Mass spectrometry hyphenated with gas 
chromatography (GC-MS) was used by Horia 
and co-workers [13]. They demonstrated that 
the levels of 23 of 58 serum metabolites and 48 
of 71 sampled from tissue were significantly 
changed in patients with lung cancer with I-IV 
stage as compared, with healthy volunteers. An 
early cancer stage was also investigated by 
other group using LC-MS method. In this study, 
the achieved AUC value based on 12 metabolites 
was 0.836 [14]. 
Urine also has a strong discriminative 
potential in lung cancer diagnosing. This was 
proven in a study performed using 1H NMR 
method by Carrola and colleagues [15]. The 
main metabolites differentiating between 
healthy controls and lung cancer patients were: 
hippurate, trigonelline, β-hydroxyisovalerate, 
α-hydroxyisobutyrate, n-acetylglutamine, and 
creatinine. They were able to develop a 
classification model, which confirmed 93 % 
sensitivity and 94 % specificity with overall 
classification rate of 93.5 %. [15]. The studies 
performed by LC-MS method on urine samples 
from cohort of 469 patients with lung cancer 
and 536 controls revealed two biomarkers: 
creatine riboside and n-acetylneuraminic acid, 
which were significantly increased in non-small 
cell lung cancer and were associated with worse 
prognosis [16].
exhaled breath condensate (eBC) seems to 
be naturally associated with lung cancer. 
Indeed, studies on eBC performed with GC-MS 
[17] and LC-MS [18] proved diagnostic 
usefulness of eBC differentiating lung cancer 
patients, CoPd patients, smokers, ex-smokers, 
and healthy controls. In addition to the above 
mentioned biofluids, also sweat should be in-
cluded, which was successfully used to diffe-
rentiate the lung cancer patients from control 
individuals with risk factors and without them 
by its analysis by LC-MS system [19]. 
Recently, a very promising study has been 
published by Shen et al.. Using two-stage study 
design and advanced metabolon platform they 
were able to identify four  metabolites, which 
may be useful biomarker candidates for 
identifying patients, who may benefit from 
platinum-based chemotherapy in advanced 
NSCLC [20]. The comprehensive review on lung 
cancer biomarkers and metabolomics methods 
has been published recently [21]. 
Breast cancer
Breast cancer (BC) is the most common 
cancer in women worldwide and the morbidity 
keeps rising. Incidence vary from 19.3 per 
100,000 women in eastern Africa to 89.7 per 
100,000 in western europe [22, 23]. Some 
decrease in the number of death caused by BC 
is observed mainly due to the improvement in 
early diagnostics [24]. Nevertheless, routine 
methods currently used to detect BC usually 
are not effective, especially in the very early 
stages [25]. 
A new approach in cancer diagnostics 
involves the use of metabolomics tools for 
blood serum and urine analysis [25, 26, 27]. 
Metabolomic-based diagnosing not only seems 
to allow discriminating healthy controls from 
BC subjects, but also differentiating metastatic 
BC from early stages of BC as well [28, 29].
Previous studies proved that BC can be 
diagnosed by NMR spectroscopy and by MS, 
both by use of serum and urine [27, 30, 31]. 
A. Lamasz et al.
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However, those metabolomic studies involved 
relatively small groups and, utilized various 
protocols and methods [32]. Therefore, a more 
integrated and coherent methodology should 
be used [33].
The GC-MS method can be used for 
metabolic profiling of serum. Using this 
method, it was possible to differentiate patients 
with BC from patients with non-malignant 
tumours, and from healthy controls. Sets of 
amino acids, fatty acids, and lysolipids allowed 
differentiating these three groups [31]. There 
is also evidence that polar compounds analysis 
has been successfully applied for metabolomic-
based BC diagnosing in tissue samples. Chae 
and co-workers used HR-MAS 1H NMR method 
for retrospective analysis in the patients with 
ductal carcinoma in situ (dCIS) diagnosed on 
preoperative biopsy. The univariate analysis 
proved that choline-containing compounds did 
not differ between the groups, while GPC/PC 
ratio, myo-inositol, and succinate were higher 
in the ‘pure’ dCIS group as compared to the 
invasive carcinoma subjects. Multivariate 
analysis oPLS-dA could discriminate to some 
degree between these two groups [34]. Com-
parable results were obtained in other groups. 
In a study based on add space 1H NMR method 
the authors were able to distinguish between 
the non-invasive intraductal carcinoma and 
invasive ductal carcinoma patients. Histidine 
con centration was significantly lower in the 
patients with invasive ductal carcinoma. In 
contrast, those patients presented higher 
concentrations of glucose, lactate, tyrosine, and 
lipids in plasma samples, as compared to the 
non-invasive carcinoma group [35]. 
It is also possible to differentiate metastatic 
BC patients from the ones with a localized, 
early-stage disease. Serum analysis with NMR 
spectroscopy identified 9 metabolites: histidine, 
acetoacetate, glycerol, pyruvate, glycoproteins 
(N-acetyl), mannose, glutamate, and phe-
nylalanine concentrations, all of which were 
significantly different, than those in the other 
studied groups [26]. 
Volatile organic compounds (VoC) from 
urine samples can also be used for BC diagnosis. 
In the study of Silva et al., gas chromatography-
mass spectrometry was used to obtain meta-
bolomic patterns of 26 BC patients and 21 
healthy individuals. Of the 79 volatile identified 
metabolites six compounds were of diagnostic 
power: (−)-4-carene, 3-heptanone, 1,2,4-tri-
methylbenzene, 2-methoxythiophene, phenol, 
and dimethylsufide. All of them were able to 
successfully discriminate between the groups 
[30]. 
More holistic approach was suggested by 
Bro et al. In a retrospective study they combined 
1H NMR data with other relevant biological and 
phenotypic information to construct a patient’s 
biocountour. with this approach the authors 
could predict an increased risk of BC, a few 
years before its occurrence with sensitivity and 
specificity well above 80 % [36]. A very interesting 
paper aiming on possible associations of diet-
related metabolites with BC risk was published 
recently by Pleydon et al.. Using Ce-MS method 
they identified a bunch of metabolites, which 
were moderately correlated with increased risk 
of estrogen receptor related to BC development 
[37]. The annually increasing literature data 
proves the usefulness of metabolomics in BC 
[33, 38].
Conclusions
data from the literature clearly demonstrate 
the usefulness of metabolomic approach in 
diagnostics of lung cancer, breast cancer, and 
many other diseases. despite this, the meta-
bolomic approach is still not routinely imple-
mented into medical protocols. This results 
from many factors. Analytical methods used for 
metabolomic research are neither standardized 
nor validated. Consequently, it is difficult to: 
compare results obtained by various research 
groups, and determine the definitive clinical 
recommen dations. Threfore we need more and 
more research to overcome these difficulties. 
However, in the future the metabolomic 
approach with fingerprinting and profiling-
based methods, combined together with 
predictive-discrimination statistical models 
should be the method of choice for preventive, 
screening, and treatment research. 
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МЕТАБОЛОМІКА – НОВИЙ ПІДХІД ДО ДІАГНОСТУВАННЯ РАКУ?  
НА ПРИКЛАДІ РАКУ ЛЕГЕНЬ ТА МОЛОЧНИХ ЗАЛОЗ 
A. Lamasz1, W. Barg2, P. Mlynarz1
1 – BIOORGANIC CHEMISTRY GROUP, FACULTY OF CHEMISTRY, WROCŁAW UNIVERSITY OF SCIENCE 
AND TECHNOLOGY, WROCŁAW, POLAND
2 – DEPARTMENT OF PHYSIOLOGY, WROCLAW MEDICAL UNIVERSITY, WROCLAW, POLAND
Вступ. Метаболоміка це відносно новий діагностичний підхід, який дозволяє аналізувати метаболічні процеси 
на рівні клітини. 
Мета дослідження та методи – огляд технології аналізу метаболоміки та її використання у клінічній практиці 
для діагностики певних злоякісних захворювань.  
Результати. Загалом, метаболомічний підхід включає три етапи: 1) відбір проб біоологічних матеріалів, 2) 
ідентифікація низькомолекулярних сполук масою до 1,0 кДа з використанням ядерного магнітного резонансу та/
або мас-спектрометрії, 3) обробка та аналіз даних. 
Сьогодні ми можемо визначити набір метаболітів, що є специфічним для певного метаболічного статусу (так 
званий «метаболічний відбиток»). Цей набір метаболітів дасть можливість оцінити певні патогенетичні ланки 
та визначитися з етіологією захворювання.  Доведено, що зміни в метаболомі передують, не лише появі перших 
клінічних ознак та симптомів, але й будь-яким змінам у клініко-лабораторних аналізах. Отже, метаболомічний 
підхід може бути  перспективним для скринінгу та ранньої діагностики.  
Висновки. Доведено, що метаболоміка дозволяє первинно діагностувати та провести диференціальний діагноз 
стадії злоякісного процесу.
КЛЮЧОВІ СЛОВА: метаболоміка; метаболіти; рак молочної залози; рак легень.
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